grant

Using a fragment-based approach to develop inhibitors of coenzyme A biosynthesis in Mycobacterium tuberculosis, the bacterium that causes tuberculosis [ 2011 - 2017 ]

Also known as: Developing new therapies to combat tuberculosis through inhibition of vitamin B5 metabolism in the organism that causes the disease

Research Grant

[Cite as http://purl.org/au-research/grants/nhmrc/1016357]

Researchers: Dr Christina Spry (Principal investigator)

Brief description The metabolism of vitamin B5 by pathogenic microorganisms has been recognised as an attractive target for developing drugs to combat various infectious diseases. The aim of the proposed work is to develop inhibitors of vitamin B5 metabolism in the bacterium that causes tuberculosis, using a powerful, multidisciplinary approach known as “fragment-based drug discovery”. This work is likely to yield potent inhibitors of the target bacterium, which could ultimately be used to treat tuberculosis.

Funding Amount $AUD 334,113.73

Funding Scheme Early Career Fellowships

Notes CJ Martin Biomedical ECF

Click to explore relationships graph
Identifiers
Viewed: [[ro.stat.viewed]]